Literature DB >> 33044037

In Reply.

Apostolos Papachristos1, Polychronis Kemos2, Haralabos Kalofonos3, Gregory Sivolapenko1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33044037      PMCID： PMC8108043          DOI： 10.1002/onco.13565

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.

Authors:  C Liu; J Yu; H Li; J Liu; Y Xu; P Song; Q Liu; H Zhao; J Xu; V E Maher; B P Booth; G Kim; A Rahman; Y Wang
Journal:  Clin Pharmacol Ther       Date:  2017-03-22       Impact factor: 6.875

2.  Correlation Between Bevacizumab Exposure and Survival Does Not Necessarily Imply Causality.

Authors:  Félicien Le Louedec; Etienne Chatelut
Journal:  Oncologist       Date:  2020-10-26

3.  Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.

Authors:  David C Turner; Anna G Kondic; Keaven M Anderson; Andrew G Robinson; Edward B Garon; Jonathan Wesley Riess; Lokesh Jain; Kapil Mayawala; Jiannan Kang; Scot W Ebbinghaus; Vikram Sinha; Dinesh P de Alwis; Julie A Stone
Journal:  Clin Cancer Res       Date:  2018-06-11       Impact factor: 12.531

4.  Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.

Authors:  Apostolos Papachristos; Polychronis Kemos; Haralabos Kalofonos; Gregory Sivolapenko
Journal:  Oncologist       Date:  2020-04-28       Impact factor: 5.837

5.  Evaluation of dosing strategy for pembrolizumab for oncology indications.

Authors:  Tomoko Freshwater; Anna Kondic; Malidi Ahamadi; Claire H Li; Rik de Greef; Dinesh de Alwis; Julie A Stone
Journal:  J Immunother Cancer       Date:  2017-05-16       Impact factor: 13.751
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.